SEC Form 4 · accession 0001209191-15-078523
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank H Valone M.D.
Officer — Chief Medical Officer
Period of report
Nov 2, 2015
Accepted (ET)
Nov 4, 2015 · 6:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2015 | M | 10,000 | $2.90 | A | 94,044 | D | |
| Common StockF1,F2 | Nov 2, 2015 | S | 8,655 | $23.0799 | D | 85,389 | D | |
| Common StockF1,F3 | Nov 2, 2015 | S | 1,345 | $23.8192 | D | 84,044 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $2.90 | Nov 2, 2015 | M | 10,000 | D | — | Jun 9, 2020 | Common Stock | 10,000 | 30,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices between $22.75 and $23.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices between $23.76 and $23.89. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Fully vested.